We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Newly Available Microarray System Focuses on Metabolic Pathway Mutations

By LabMedica International staff writers
Posted on 06 Jun 2011
Print article
Image: qBiomarker Somatic Mutation PCR Arrays (Photo courtesy of Qiagen).
Image: qBiomarker Somatic Mutation PCR Arrays (Photo courtesy of Qiagen).
A microarray analysis system for rapid and accurate mutation profiling in basic research and drug discovery has now become commercially available.

Acquisition of somatic mutations in human genomic DNA (gDNA) is an important event during tumorigenesis and cancer progression. Somatic mutations occur as single mutations within a gene, multiple mutations within a gene, or mutations present across related genes in a variety of cancers. Cells may respond differently to treatment regimens based on their somatic mutation profile. For example, the mutation status of the EGFR and KRAS genes can predict the physiological response to certain drugs targeting these molecules.

The utility of individual and multiple somatic mutation status information in identifying key signaling transduction disruptions has been demonstrated in numerous research studies. To this end QIAGEN (Venlo, The Netherlands) has launched a line of 96- and 384-well microarray products designed for rapid and accurate mutation profiling.

The pathway-focused qBiomarker Somatic Mutation PCR Arrays are translational research tools that allow rapid and accurate profiling of somatic mutation status for a pathway-focused set of genes and key downstream and associated signaling genes. For example, the ErbB2/HER2/neu Pathway qBiomarker Somatic Mutation PCR Array is designed for studying mutations in the context of the ErbB2 pathway and has the potential for discovering and verifying drug target biomarkers for a variety of human cancers involving the ErbB2 signaling pathway and downstream effectors.

Studies using the array system require approximately two hours from sample to result and are easy to perform: the DNA is extracted from the sample, amplified if needed, and then used for the PCR array with any block-based real-time cycler.

Arrays are available that cover mutations that have been selected from comprehensive databases and literature reviews based on their biological relevance and frequency of occurrence.

Related Links:

QIAGEN


Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Antipsychotic TDM AssaysSaladax Antipsychotic Assays
New
LH ELISA
Luteinizing Hormone ELISA
New
Automated Cell Counter
QuadCount

Print article

Channels

Clinical Chemistry

view channel
Image: The new saliva-based test for heart failure measures two biomarkers in about 15 minutes (Photo courtesy of Trey Pittman)

POC Saliva Testing Device Predicts Heart Failure in 15 Minutes

Heart failure is a serious condition where the heart muscle is unable to pump sufficient oxygen-rich blood throughout the body. It ranks as a major cause of death globally and is particularly fatal for... Read more

Hematology

view channel
Image: The smartphone technology measures blood hemoglobin levels from a digital photo of the inner eyelid (Photo courtesy of Purdue University)

First-Of-Its-Kind Smartphone Technology Noninvasively Measures Blood Hemoglobin Levels at POC

Blood hemoglobin tests are among the most frequently conducted blood tests, as hemoglobin levels can provide vital insights into various health conditions. However, traditional tests are often underutilized... Read more

Immunology

view channel
Image: Under a microscope, DNA repair is visible as bright green spots (“foci”) in the blue-stained cell DNA. Orange highlights actively growing cancer cells (Photo courtesy of WEHI)

Simple Blood Test Could Detect Drug Resistance in Ovarian Cancer Patients

Every year, hundreds of thousands of women across the world are diagnosed with ovarian and breast cancer. PARP inhibitors (PARPi) therapy has been a major advancement in treating these cancers, particularly... Read more

Microbiology

view channel
Image: HNL Dimer can be a novel and potentially useful clinical tool in antibiotic stewardship in sepsis (Photo courtesy of Shutterstock)

Unique Blood Biomarker Shown to Effectively Monitor Sepsis Treatment

Sepsis remains a growing problem across the world, linked to high rates of mortality and morbidity. Timely and accurate diagnosis, along with effective supportive therapy, is essential in reducing sepsis-related... Read more

Pathology

view channel
Image: The artificial intelligence models can personalize immune therapies in oncology patients (Photo courtesy of 123RF)

AI Tool Identifies Novel Genetic Signatures to Personalize Cancer Therapies

Lung cancer and bladder cancer are among the most commonly diagnosed cancers globally. Researchers have now developed artificial intelligence (AI) models designed to personalize immune therapies for oncology... Read more

Technology

view channel
Image: Schematic diagram of nanomaterial-based anti-epileptic drug concentration diagnostic technology (Photo courtesy of KRISS)

Nanomaterial-Based Diagnostic Technology Accurately Monitors Drug Therapy in Epilepsy Patients

Many patients with epilepsy take anti-epileptic drugs to control frequent seizures in their daily lives. To optimize treatment and avoid side effects from overdosing, it is crucial for patients to regularly... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.